Results 51 to 60 of about 49,840 (301)

Full Issue: Volume 13, Issue 1 - Winter 2018 [PDF]

, 2018
Full Issue: Volume 13, Issue 1 - Winter ...

core   +1 more source

Alkaline Phosphatase‐Activated NIR‐II AIEgens Nanosystem for Surgical and Postoperative Closed‐Loop Therapy of Advanced Osteosarcoma

Advanced Science, EarlyView.
This study designed a tumor microenvironment‐responsive AIEgen nanoparticle for near‐infrared photoimmunotherapy, which inhibits primary tumors and metastasis by promoting pyroptosis and suppressing aerobic glycolysis. ABSTRACT In advanced osteosarcoma, tumor invasion often prevents complete resection, and immunotherapy is limited by the tumor's ...
Kaiyuan Liu, Ruotong Li, Li Zhang, Hengli Lu, Binhui Yang, Qian Hu, Yining Tao, Haoran Mu, Jing Han, Pengfei Zan, Jiakang Shen, Dongqing Zuo, Hongsheng Wang, Wei Sun, Xingjun Zhu   +14 more
wiley   +1 more source

The Role of Endobronchial Ultrasound as an Adjuvant for Endobronchial Tumor Debulking

Journal of Advanced Lung Health
Endobronchial tumors often present with life-threatening central airway obstruction, producing disabling symptoms and procedural challenges. Conventional rigid bronchoscopy with laser, cryotherapy, or mechanical debulking remains the mainstay of ...
Abhinav Choubey, Alkesh Khurana
doaj   +1 more source

Metabolic active peritoneal sites affect tumor debulking in ovarian and peritoneal cancers

Journal of Ovarian Research, 2020
Rationale and objectives To evaluate the impact of metabolic parameters in the peritoneal cavity on the likelihood of achieving complete tumor debulking in patients with ovarian and peritoneal cancers.
Tung Tung Tsoi, Keith W. H. Chiu, M. Y. Chu, Hextan Y. S. Ngan, Elaine Y. P. Lee   +4 more
doaj   +1 more source

NIR Ratiometric Fluorescent Antibody‐Drug Conjugate for Metastatic Ovarian Cancer Theranostics and Treatment Response Monitoring

Advanced Science, EarlyView.
In vivo optical imaging enhances antibody‐drug conjugate (ADC) optimization by enabling real‐time monitoring of stimulus‐responsive drug behavior. We report n501‐CYMMAF, a ratiometric theranostic with strong target affinity and low‐dose efficacy for ovarian metastasis.
Cheng Li, Zezhong Yu, Tao Pu, Yanling Wu, Gang Wang, Youhua Xie, Tianlei Ying, Zhenlin Yang, Yibing Shi   +8 more
wiley   +1 more source

The Outcomes of Primary Debulking Surgery and Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

Indonesian Journal of Obstetrics and Gynecology, 2016
Objective: To compare the outcomes and survival rate of primary debulking surgery with neoadjuvant chemotherapy. Method: We selected advanced ovarian cancer patients from medical records.
Dino Rinaldy, Andrijono Andrijono, Bambang Sutrisna   +2 more
doaj   +1 more source

Complete response of skull base inverted papilloma to chemotherapy: Case report. [PDF]

, 2017
BackgroundInverted papilloma (IP) is the most common benign sinonasal neoplasm. Endoscopic techniques, improved understanding of pathophysiology, and novel surgical approaches have allowed rhinologists to treat IPs more effectively, with surgery being ...
Frederick, John W, Kuan, Edward C, Lim, Dean W, Palma Diaz, Miguel F, Suh, Jeffrey D   +4 more
core  

Trametinib in Adults with Neurofibromatosis Type 1‐Related Symptomatic Plexiform Neurofibromas

Annals of Neurology, EarlyView.
Objective Mitogen‐activated protein kinase kinase inhibitors have shown promising results in treatment of plexiform neurofibromas in neurofibromatosis type 1 patients, but data in adults are limited. The aim of this phase 2 study was to investigate the efficacy and safety of trametinib in adults with neurofibromatosis type 1.
D. Christine Noordhoek, David F. Hanff, Pim J. French, Sarah A. van Dijk, Erik A.C. Wiemer, Olivier C. Manintveld, Martin J. van den Bent, Walter Taal   +7 more
wiley   +1 more source

Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy [PDF]

, 2017
BACKGROUND: Current standard neoadjuvant treatment for advanced ovarian cancer is 3-weekly platinum-based chemotherapy (CP3w). Patients unable to have interval debulking surgery (IDS) or with significant residual disease have a poor outcome to CP3w ...
Hackshaw, A, Kristeleit, R, Ledermann, JA, Luvero, D, MacDonald, N, McCormack, M, Milani, A, Mould, T, Olatain, A, Raja, F, Widschwendter, M   +10 more
core   +1 more source

Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients

International Journal of Cancer, EarlyView.
What's New? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman, Nahal Masrour, Naina Patel, Anna M. Piskorz, Robert Brown, James D. Brenton, Iain A. McNeish, James M. Flanagan   +7 more
wiley   +1 more source